Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine Hemorrhage

10. November 2026 aktualisiert von: Dr. Yong Cao, Beijing Tiantan Hospital

A Multicenter, Randomized, Open-Label, Blinded-Endpoint Clinical Trial of Neuronavigation-Guided Stereotactic Aspiration Combined With Tenecteplase for Acute Brainstem Hemorrhage

This multicenter, randomized, open-label, blinded-endpoint clinical study aims to evaluate the safety, feasibility, and potential clinical benefits of neuronavigation-guided stereotactic hematoma aspiration combined with tenecteplase in patients with acute primary brainstem hemorrhage.A total of 140 patients will be randomly assigned in a 1:1 ratio to receive either stereotactic hematoma aspiration combined with tenecteplase and standard medical treatment or standard medical treatment alone.The primary outcome is the proportion of patients with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. Safety outcomes include mortality, symptomatic rebleeding, and intracranial infection.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

140

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100070
        • Rekrutierung
        • Beijing Tiantan Hospital, Capital Medical University
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 79 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age ≥18 years and <80 years.
  • Diagnostic CT completed within 24 hours after symptom onset. Patients with unknown onset time will be excluded. For patients with symptoms first noted during sleep, the time last known well will be considered the onset time.
  • Acute primary brainstem hemorrhage confirmed by head CT, with the predominant hematoma location in the pons (>50% of the hematoma located in the pons); hematoma volume 5-10 mL as measured by the ABC/2 method. The hematoma must be located within the brainstem parenchyma rather than primarily within the ventricles, although extension into the third or fourth ventricle is permitted. For unilateral hemorrhage, a hematoma volume of 3-5 mL is permitted.
  • A repeat CT scan performed 6 hours after symptom onset confirms that the hematoma volume remains within the eligibility range.
  • Glasgow Coma Scale (GCS) score ≥5 and <12 at enrollment.
  • Randomization initiated between 6 and 12 hours after the diagnostic CT.
  • Systolic blood pressure (SBP) <180 mmHg maintained during the 6 hours immediately before randomization.
  • Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  • Voluntary participation in the study with written informed consent provided by the participant or legally authorized representative, as applicable.

Exclusion Criteria:

  • Supratentorial hemorrhage, posterior fossa hemorrhage, or cerebellar hemorrhage.
  • Signs of extremely severe disease, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, or loss of spontaneous respiration.
  • The predominant portion of the hematoma involves the midbrain or medulla.
  • Brainstem hemorrhage secondary to another cerebrovascular or neurological disorder, including cerebral vascular malformation, intracranial aneurysm, other cerebrovascular abnormalities, moyamoya disease, hemorrhagic transformation of ischemic stroke, or hemorrhage related to a neurological tumor.
  • Unstable infratentorial space-occupying lesion, transtentorial herniation, or foramen magnum herniation.
  • Previous history of brainstem hemorrhage.
  • Irreversible brainstem dysfunction, defined as a GCS score ≤4 or ≥12.
  • An indication for craniotomy because of either: (a) progressive deterioration of consciousness; or (b) preoperative cerebral herniation, including signs associated with foramen magnum herniation or uncal herniation.
  • CT evidence indicating a high risk of rebleeding, including a spot sign.
  • Platelet count <100,000/mL or international normalized ratio (INR) >1.4.
  • Any irreversible coagulation disorder, including hemophilia or von Willebrand disease, use of anticoagulants such as warfarin, or a known disorder of clot formation, including a hypercoagulable state.
  • Inability to maintain INR ≤1.4 despite treatment with short- or long-acting hemostatic agents, including recombinant factor VIIa, fresh frozen plasma, or vitamin K.
  • Requirement for long-term anticoagulation. Patients who can undergo temporary reversal of anticoagulation but cannot discontinue warfarin or other anticoagulants for the subsequent 30 days will be excluded.
  • Use within 1 week before symptom onset of dabigatran, apixaban, rivaroxaban, tirofiban, ticagrelor, cilostazol, or clopidogrel.
  • Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary systems, or respiratory tract bleeding.
  • Superficial bleeding at a vascular access site (e.g., venous cutdown or arterial puncture) or surgical site.
  • Positive urine or serum pregnancy test in a premenopausal woman without documented surgical sterilization.
  • Known hypersensitivity to tenecteplase.
  • Previous participation in this study with completed randomization.
  • Concurrent participation in another interventional medical study or clinical trial. Participation in an observational study, natural history study, or epidemiological study without an interventional component is permitted.
  • Before randomization, the participant is not expected to survive through the Day 365 follow-up, or has requested do-not-resuscitate (DNR) or do-not-intubate (DNI) status.
  • Any serious concomitant disease expected to substantially affect prognosis, including severe hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune, or hematologic disease.
  • Presence of a mechanical prosthetic heart valve. A bioprosthetic heart valve is permitted.
  • Known embolic risk, including a history of left-sided intracardiac thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.
  • Any condition requiring immediate emergency treatment outside the study protocol, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, loss of spontaneous respiration, signs of cerebral herniation, progressive respiratory or circulatory failure, or a multidisciplinary determination that immediate craniotomy for hematoma evacuation, decompressive craniectomy, emergency external ventricular drainage, or other emergency treatment is required. Study screening and randomization must not delay necessary emergency treatment.
  • The participant requests conservative treatment or conventional open microsurgical treatment.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Stereotactic Aspiration Combined With Tenecteplase

Participants will receive neuronavigation-guided stereotactic hematoma aspiration followed by intralesional tenecteplase administration, in addition to standard medical treatment.

Neuronavigation-guided stereotactic hematoma aspiration and catheter drainage will be performed within 6 hours after randomization.

Tenecteplase (0.155 mg per dose) will be administered into the hematoma cavity through the drainage catheter after postoperative CT confirms hematoma stability, for up to three doses.

Andere Namen:
  • rhTNK-tPA

Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation.

Aktiver Komparator: Standard Medical Treatment

Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of Participants With GCS Score >8
Zeitfenster: 90 days after randomization

Proportion of participants with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days.

90 days after randomization
All-Cause Mortality
Zeitfenster: Within 30 days after randomization.

Proportion of participants who die from any cause within 30 days after randomization.

Within 30 days after randomization.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Zeitfenster
7-Day All-Cause Mortality
Zeitfenster: Within 7 days
Within 7 days
Symptomatic Rebleeding
Zeitfenster: Within 72 hours after tenecteplase administration
Within 72 hours after tenecteplase administration
Intracranial Bacterial Infection
Zeitfenster: Within 30 days
Within 30 days
Serious Adverse Events (SAEs)
Zeitfenster: Within 30 days
Within 30 days
Adverse Events (AEs)
Zeitfenster: Within 30 days
Within 30 days
Serious Adverse Events (SAEs)
Zeitfenster: Within 365 days
Within 365 days
Adverse Events (AEs)
Zeitfenster: Within 365 days
Within 365 days
Proportion With GCS Increase ≥3 Points
Zeitfenster: 30 days
30 days
Proportion With Recovery of Consciousness
Zeitfenster: 30 days
30 days
Proportion With mRS 0-3
Zeitfenster: 90 days
90 days
Proportion With mRS 0-3
Zeitfenster: 365 days
365 days
Change in GCS Score Over Time
Zeitfenster: From baseline through 90 days after randomization
From baseline through 90 days after randomization

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. April 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2028

Studienabschluss (Geschätzt)

31. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

10. November 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

10. November 2026

Zuerst gepostet (Tatsächlich)

16. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • LX-2026-0001

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .